Exome sequencing has higher diagnostic yield compared to simulated disease-specific panels in children with suspected monogenic disorders
Authors:
- Melbourne Genomics Health AllianceMAMelbourne Genomics Health Alliance
- Sebastian LunkeSLSebastian Lunke
- Susan M. WhiteSWSusan M. White
- Tiong Yang TanTTTiong Yang Tan
- 16 February 2018
- journal article
- research article
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 26 (5) , 644-651
Abstract
As test costs decline, whole-exome sequencing (WES) has become increasingly used for clinical diagnosis, and now represents the primary alternative to gene panel testing for patients with a suspected genetic disorder. We sought to compare the diagnostic yield of singleton-WES with simulated application of commercial gene panels in children suspected of having a genetically heterogeneous condition. Recruitment, singleton-WES and phenotype-driven variant analysis was completed for 145 paediatric patients. At recruitment, clinicians were required to propose commercial gene panel tests as an alternative to WES and nominate a phenotype-driven candidate gene list. In WES-diagnosed children, three commercial options for each proposed panel were identified and evaluated for hypothetical diagnostic yield assuming 100% analytical sensitivity and specificity. We compared the price of WES with the least costly panel in WES-diagnosed children. In WES-undiagnosed children, we evaluated the exonic coverage of their phenotype-driven gene list using aggregate data. WES diagnoses were made in genes not included in at least one-of-three commercial panels in 42% of cases. Had a panel been selected instead, 23% of WES-diagnosed children would not have been diagnosed. In 26% of cases, the least costly panel option would have been more expensive than WES. Evaluation of WES coverage found that at the most stringent level of 20× coverage, the likelihood of missing a clinically relevant variant in a candidate gene list was maximally 8%. The broader coverage of WES makes it a superior alternative to gene panel testing at similar financial cost for children with suspected complex monogenic phenotypes.Keywords
This publication has 39 references indexed in Scilit:
- Improved diagnostic yield compared with targeted gene sequencing panels suggests a role for whole-genome sequencing as a first-tier genetic testGenetics in Medicine, 2018
- Lessons learned from additional research analyses of unsolved clinical exome casesGenome Medicine, 2017
- A prospective evaluation of whole-exome sequencing as a first-tier molecular test in infants with suspected monogenic disordersGenetics in Medicine, 2016
- Clinical application of whole-exome sequencing across clinical indicationsGenetics in Medicine, 2016
- Comprehensive gene panels provide advantages over clinical exome sequencing for Mendelian diseasesGenome Biology, 2015
- Solving the molecular diagnostic testing conundrum for Mendelian disorders in the era of next-generation sequencing: single-gene, gene panel, or exome/genome sequencingGenetics in Medicine, 2015
- Effectiveness of exome and genome sequencing guided by acuity of illness for diagnosis of neurodevelopmental disordersScience Translational Medicine, 2014
- Variant detection sensitivity and biases in whole genome and exome sequencingBMC Bioinformatics, 2014
- A Post-Hoc Comparison of the Utility of Sanger Sequencing and Exome Sequencing for the Diagnosis of Heterogeneous DiseasesHuman Mutation, 2013
- The Human Gene Mutation Database: building a comprehensive mutation repository for clinical and molecular genetics, diagnostic testing and personalized genomic medicineHuman Genetics, 2013